Viniferin and its derivatives: a comprehensive review of structural variations and promising pharmacological applications in disease prevention and therapeutic development

Abstract

Viniferin, a resveratrol-derived compound that belongs to a group of plant-produced stilbenoids, functions as a natural defense against microbial invasion, toxins, infections, and ultraviolet radiation. Alpha-(α-) viniferin (trimer), beta-(β-) viniferin (dimer), delta-(δ-) viniferin (oxidative dehydrodimer), epsilon-(ε-) viniferin (distinct dehydrodimer), gamma-(γ-) viniferin (isomeric oligomer), vitisin A (R-viniferin), and vitisin B (R2-viniferin) are structurally diverse forms with distinct pharmacological activities. Antioxidant studies showed that ε-viniferin exhibited a 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging half-maximal inhibitory concentration (IC₅₀) of about 80 µM. Also, suppression of nuclear factor kappa B, cyclooxygenase-2, and prostaglandin E₂ are anti-inflammatory mechanisms. R2-viniferin demonstrated an IC₅₀ of 9.7 µM against hepatocellular carcinoma HepG2 cells at 72 h, mediated through apoptosis and cell-cycle arrest, according to anticancer studies that demonstrated dose-dependent cytotoxicity. There have been reports of additional activity against models of glioblastoma and prostate cancer. In metabolic disorders, oral α-viniferin (20-40 mg/kg/day) improved lipid and glucose homeostasis in mice fed a high-fat diet, and it additionally improved liver and renal biomarkers such as blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransaminase. Several bacterial strains have shown signs of preliminary antimicrobial action. By reducing excitotoxicity and oxidative stress, viniferins also have neuroprotective effects. They also have anti-melanogenic properties by blocking the tyrosinase and melanogenesis pathways. Collectively, viniferins demonstrate pleiotropic pharmacologic activities by defined molecular mechanisms and quantifiable dose-dependent effects. The properties classify viniferins as new multifunctional drug candidates for discovery and nutraceuticals, but they highlight the need for standardized pharmacologic assays, further preclinical validation, and pharmacokinetic optimization towards clinical use.